The proportion of export of pharmaceutical machinery in China is increasing

In recent years, China's pharmaceutical industry has developed rapidly, which brings great development space to the pharmaceutical machinery and equipment industry. At the same time, with the support of the "made in China 2025" plan and many favorable policies, the pharmaceutical equipment industry in China has ushered in good opportunities, the scale of the industry continues to expand, the capability of independent innovation and R & D gradually improves, and the key technology areas are also constantly breaking through. Under many factors, the willingness and pace of "going out" of domestic pharmaceutical machinery enterprises are accelerated, the product export growth rate is obvious, and the proportion of export is also increasing year by year.

According to industry statistics, in 2017, the export delivery value of 288 pharmaceutical machinery enterprises in China reached 264961 million yuan. Among them, the top three pharmaceutical machinery enterprises in terms of export delivery value are Haomai machinery, dongfulong and truking technology. Shandong Haomai Machinery Manufacturing Co., Ltd. is an enterprise mainly engaged in the production of heat transfer equipment, mainly engaged in pressure vessels, heat exchangers, spiral wound heat exchangers, condensers and other products. It has considerable strength and scale in the machinery and industry equipment industry. The company has successively obtained ISO9001 quality system certification, A1 / A2 type pressure vessel design and manufacturing certification of National Quality Supervision Bureau, CrN certification of Canadian boiler and pressure vessel department, ASME certification of American Society of mechanical engineers and other qualification certificates, and is in the process of occupational health and environmental safety certification. In just a few years, the company's machining strength has passed the certification of seven world top 500 enterprises, including General Electric of the United States, Siemens of Germany, Toshiba of Japan, caterpillar of the United States, ThyssenKrupp of Germany, PetroChina and Sinopec, and has carried out extensive cooperation in the field of machining.

Dongfulong Shanghai dongfulong is mainly engaged in technical development, technical consultation, technology transfer and technical services in the field of pharmaceutical equipment science and technology, production and development of industrial liquid distribution system, liquid waste inactivation system device, drainage treatment equipment, water system and clean pipeline system, sales of self-produced products and provision of relevant supporting installation and maintenance services, including the above products Wholesale, import and export of similar goods, commission agency (excluding auction), and provide relevant supporting services. On September 11, 2018, Dong Fulong said that in 2017, the company's export revenue to the United States accounted for 7% of its export overseas business and 2% of its total revenue. The Sino US trade dispute has no significant impact on the company as a whole.

Truking Technology Co., Ltd. is one of the major enterprises in the world pharmaceutical equipment industry. The main business is medical equipment and its overall solutions, and takes the lead in promoting the research and development of smart pharmaceutical plants. As of December 31, 2018, truking filed 2769 Chinese patent applications and 1609 authorized patents. In addition, 25 PCT international patent applications were filed, and 12 patent authorizations were obtained in the United States, Japan, Russia and India. The products have been exported to more than 30 countries and regions such as Asia, Europe, South America and the former Soviet Union. The international market share is increasing rapidly year by year. In 2017, truking technology semiannual report showed that the international market developed steadily. In the first half of the year, the operating revenue of the international market accounted for about 25% of the company's total revenue. The company's international business publicity and promotion efforts were further strengthened, and the international market was further expanded, making the export revenue in the reporting period increased by about 20% compared with the same period in 2016, accounting for about 23% of the total revenue. In general, in recent years, the domestic pharmaceutical machinery industry is rising, and the technical standards of some products are gradually in line with the world, realizing the transformation of domestic pharmaceutical machinery from low-level repetitive imitation to combination of imitation and creation, and then to independent R & D and innovation.

Domestic pharmaceutical machinery enterprises actively participate in the international pharmaceutical machinery exhibition by virtue of good policies of "going out" Products and technology to overseas markets. Dongfulong, truking and other leading enterprises have gradually emerged in the international market, and their products and technologies have gradually occupied a certain position in the international market, breaking the monopoly situation of foreign enterprises for decades.

In view of the future development direction of China's pharmaceutical machinery industry, Zheng Xiaodong, chairman of Shanghai dongfulong, believes that in the era of industry 4.0, intelligent factory and intelligent production are the major trend of development. He said that intelligent production system and process control have been applied in every production line of Dongfu long. In the future, Dongfu long would like to achieve the integrated implementation of "human, machine, material, law, testing and environment" of GMP system, and become the global "intelligent drug factory deliverer".